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Abstract
β-ionone (βI), a cyclic isoprenoid, and geraniol (GO), an acyclic monoterpene, represent a promising class of dietary chemo-
preventive agents against cancer, whose combination could result in synergistic anticarcinogenic effects. The chemopreventive 
activities of βI and GO were evaluated individually or in combination during colon carcinogenesis induced by dimethylhydrazine 
in 48 3-week-old male Wistar rats (12 per group) weighing 40-50 g. Animals were treated for 9 consecutive weeks with βI (16 
mg/100 g body weight), GO (25 mg/100 g body weight), βI combined with GO, or corn oil (control). Number of total aberrant 
crypt foci (ACF) and of ACF ≥4 crypts in the distal colon was significantly lower in the GO group (66 ± 13 and 9 ± 2, respectively) 
compared to control (102 ± 9 and 17 ± 3) and without differences in the βI (91 ± 11 and 14 ± 3) and βI+GO groups (96 ± 5 and 
19 ± 2). Apoptosis level, identified by classical apoptosis morphological criteria, was significantly higher in the GO group (1.64 
± 0.06 apoptotic cells/mm2) compared to control (0.91 ± 0.07 apoptotic cells/mm2) in the distal colon. The GO group presented 
a 0.7-fold reduction in Bcl-2 protein expression (Western blot) compared to control. Colonic mucosa concentrations of βI and 
GO (gas chromatography/mass spectrometry) were higher in the βI and GO groups, respectively, compared to the control and 
βI+GO groups. Therefore, GO, but not βI, represents a potential chemopreventive agent in colon carcinogenesis. Surprisingly, 
the combination of isoprenoids does not represent an efficient chemopreventive strategy.
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Colon cancer, which is the second most prevalent type 
of cancer in the world, is an important public health problem 
that is related to life style, especially eating habits (1). 
Bioactive compounds present in foods, such as isoprenic 
derivatives found in fruits and vegetables, are potential 
chemopreventive agents against cancer (2,3). Promising 
dietary isoprenoids are β-ionone (βI), a cyclic isoprenoid, 
the product of β-carotene degradation, which is present 
mainly in grapes and wine aromatizers, and geraniol (GO), 
an acyclic monoterpene, which is an important constituent of 
the essential oils of ginger, lemon, lime, orange, and nutmeg 
(Figure 1). Both compounds are of interest to the detergent, 
perfume and food industries because of their floral aromatics 
and antifungal and antioxidant properties (4,5). 
Several in vitro studies have shown that βI and GO 
suppressed cell proliferation and/or stimulated apoptosis 
in diverse tumor lines, including Caco-2 human colon 
adenocarcinoma cells (6,7). In the few available in vivo 
studies, both compounds exerted chemopreventive activity 
against hepatocarcinogenesis in rats (8-10). GO inhibited 
the growth of mammary and pancreatic neoplasms in rats 
and hamsters, respectively (11,12), and proved to be an 
effective adjuvant in the treatment with 5-fluorouracil of 
human colorectal cancer cells transplanted in Swiss nu/
nu mice (13). βI also reduced the incidence of mammary 
neoplasms in rats (3,11) and, more recently, it was shown 
to inhibit the number and size of preneoplastic lesions 
(PNLs) in the colon when administered in the diet to F344 
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rats (14). Similarly, other isoprenoids such as perillyl alcohol 
(15), squalene (16), geranylgeraniol, farnesol, and lanosterol 
(17,18) also showed chemopreventive activity in a colon 
carcinogenesis model induced by azoxymethane. 
One mechanism of action proposed for the chemopre-
ventive action of isoprenoids is related to the suppression 
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase activity (6,19), which is frequently elevated and 
deregulated in PNLs and neoplastic tissues (2). The inhibition 
of HMG-CoA reductase and intermediates of the mevalonate 
pathway is related to the suppression of cell proliferation and 
induction of apoptosis (2,6,20). The Bcl-2 family of proteins 
has also been implicated in cell death induction by dietary 
isoprenoids (21,22) and reports of changes in expression 
of Bcl-2 in colon carcinogenesis confirm that this protein 
may be involved in the primary mechanism of homeosta-
sis in the colonic epithelium (23). Additive and synergistic 
inhibitory effects have been described after treatment of 
neoplastic cell lines with a combination of cyclic and acyclic 
isoprenoids (24,25). 
Because βI and GO had chemopreventive activity in dif-
ferent models (8-10,12), including colon carcinogenesis in the 
case of βI (14), we hypothesized that the combination of βI 
and GO could result in synergistic chemopreventive activity. 
Therefore, we investigated the chemopreventive potential of 
the combination of βI and GO during the initiation and post-
initiation phases of a rat colon carcinogenesis model induced 
by dimethylhydrazine (DMH). The parameters evaluated 
included aberrant crypt foci (ACF), which are considered 
to be PNLs and are widely used as a colon carcinogenesis 
biomarker (26), plasma concentrations of total cholesterol, 
DNA damage (Comet test), expression of proliferating cell 
nuclear antigen (PCNA) and Bcl-2 proteins, and concentra-
tions of βI and GO in colonic samples.
Material and Methods 
Chemicals
βI (4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3(E)-buten-2-
one; 95%), GO (trans-3,7-dimethyl-2,6-octadien-1-ol; 98%) 
and DMH (>99%) were purchased from Sigma (USA). The 
commercial diet was purchased from Purina (Brazil), and 
the corn oil (CO) was from Mazola® (Brazil). The polyclonal 
anti-Bcl-2 rabbit antibody was purchased from Santa Cruz 
Biotechnology (USA). The monoclonal anti-PCNA, second-
ary biotinylated antibody and streptavidin-biotin-peroxidase 
complex (StrepABComplex/HRP Duet, Mouse/Rabbit) were 
purchased from Dako (Denmark). The nitrocellulose mem-
brane (Hybond TM-C extra), ECL chemiluminescence kit 
and ECL-advanced chemiluminescence kit were purchased 
from Amersham Biosciences (USA). The total plasma cho-
lesterol kit was purchased from BioSystems (Spain). NE-
PER, T-PER and BCA protein assay kits were purchased 
from Pierce (USA). All other chemicals were of the highest 
available quality.
Animals and experimental protocol
Three-week-old male Wistar rats from the colony of the 
Faculdade de Ciências Farmacêuticas, Universidade de 
São Paulo, were used. The animals, initially weighing 40-
50 g, were maintained in cages in groups of 4 at a constant 
temperature (22°C) and on a 12-h light-dark cycle and 
received water and commercial diet ad libitum. At the end 
of a 7-day acclimatization period, with the exception of 6 
rats not subjected to any experimental procedure (Normal 
(N) group), 48 animals (12 animals per group) were treated 
daily for 9 consecutive weeks with: βI (βI group; 16 mg/100 
g body weight), GO (GO group; 25 mg/100 g body weight) 
or βI combined with GO (βI+GO group; βI (16 mg/100 g 
body weight) plus GO (25 mg/100 g body weight) dissolved 
in CO (0.25 mL/100 g body weight). Animals receiving only 
CO (0.25 mL/100 g body weight) were used as controls (CO 
group). On the 3rd and 4th weeks of treatment, the CO, βI, 
GO and βI+GO groups received ip injections of DMH (40 
mg/kg body weight) twice a week (27). After 9 weeks of 
treatment, the animals were euthanized by exsanguination 
under anesthesia (Figure 2). The study was approved by 
the Ethics Committee for Animal Research of the Faculty of 
Pharmaceutical Sciences, University of São Paulo (Proto-
col #75). At autopsy, the colons were opened and divided 
longitudinally into 2 hemicolons; one hemicolonic segment 
was fixed flat in 70% ethanol and divided into 2 regions: 
proximal and distal. The other hemicolonic segment had its 
mucosa scraped and was stored at -80°C (28,29) for later 
determination of DNA damage (Comet assay), PCNA and 
Bcl-2 expression and βI and GO concentration.
Quantification of ACF in the colonic mucosa 
ACF were scored as previously described (26). Colonic 
segments were stained for 10 min with 0.02% methylene 
blue in phosphate-buffered saline (PBS; 2.7 mM KCl, 8.1 
mM Na2PO4, 1.5 mM KH2PO4, 0.14 M NaCl, pH 7.6) (27). 
Methylene blue-stained ACF, analyzed from the mucosal 
surface by transmitted light at 40X magnification, appeared 
as collections of elevated crypts with increased staining and 
Figure 1. Chemical structure of the acyclic isoprenoid geran-
iol (trans-3,7-dimethyl-2,6-octadien-1-ol) and the cyclic iso-
prenoid β-ionone (4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3(E)-
buten-2-one).
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expanded pericryptal spaces (26-28). The ACF location (distal 
or proximal colon) and the multiplicity of each focus (number 
of crypts/ACF) were recorded.
Total plasma cholesterol concentration 
Blood was collected by puncture of the abdominal aorta 
at the time of euthanasia. Immediately after collection, it was 
placed in centrifuge tubes containing 5 mg EDTA and cen-
trifuged at 3500 g, 4°C for 10 min. Total plasma cholesterol 
concentration was determined using an enzymatic-spectro-
photometric technique (10). Analysis was performed at 500 
nm with a Hitachi U 110 spectrophotometer (Japan).
Colonic DNA strand breakage (single-cell gel electro-
phoresis - Comet test)
Colonic DNA strand breakage was evaluated in colonic 
mucosa samples stored at -80°C using the Comet assay as 
described previously (9). The tissues were smoothly homog-
enized in PBS under refrigeration, and filtered. The isolated 
cells were then immobilized in a low-melting agarose matrix 
on a glass slide. The slides were then transferred to the lysis 
solution (2.5 M NaCl, 100 mM EDTA, 10 mM Trizma Base, 
10% DMSO, 1% N-laurylsarcosine, pH adjusted to 10, and 
addition of 1% Triton X-100). After 1 h, the slides were washed 
three times for 20 min with water and placed in a horizontal 
electrophoresis unit containing the running buffer (300 mM 
NaOH and 1 mM EDTA, pH >13) where they remained im-
mersed for 20 min at 5°C. Electrophoresis was performed 
for 20 min at 0.9 V/cm at 5°C. The resulting comets were 
neutralized with 0.4 M Tris three times for 5 min and stained 
with silver nitrate. Normal rat colonic tissues, treated or not 
with hydrogen peroxide (HP; 10% final concentration, 5 min 
at room temperature and sonication) were used as positive 
and negative controls, respectively.
The length of the comets was evaluated using a previ-
ously described image analysis system (8,9). One hundred 
nucleoids per animal were randomly analyzed (50 images 
per slide) and encoded slides were scored blindly. The vi-
ability of the colonic mucosa cells was indirectly determined 
by analyzing the comet images after silver staining. 
Apoptosis analysis 
Apoptosis was identified in hematoxylin-eosin (HE)-
stained proximal and distal colon sections for each animal 
from the CO, βI, GO, and βI+GO groups (27). Apoptosis 
was evaluated as total number of apoptotic cells in normal-
appearing colonic crypt areas measured in 10 random micro-
scopic fields consecutive (40X objective). This analysis was 
performed using an Image QWin Pro Plus Image Analysis 
System (Leica Imaging Systems Ltd., England) connected 
to a Leica DM2500 microscope. The image input was per-
formed using a Leica DFC300FX digital CCD camera, and 
image processing, binarization and measurement were 
performed using a standard Leica QWin V3 program. Colonic 
crypt segmentation was performed by setting an automatic 
threshold level or interactively, by manual tracing, when 
necessary. The morphological criteria for the identification 
of apoptotic colonic cells (i.e., with cellular retraction and 
condensation, condensed or fragmented nuclear chromatin 
and formation of apoptotic bodies) in HE-stained sections 
were used as previously described (27). Data are reported 
as mean number of apoptotic cells per crypt area analyzed 
(mm2) per group. 
PCNA and Bcl-2 Western blot analysis
Total and cytoplasmic protein extracts were prepared 
from the colonic mucosa samples of the animals using the 
T-PER and NE-PER reagents, respectively. Protein con-
centration was determined with the BCA protein assay kit. 
Samples of 150 µg total protein and of 450 µg cytoplasmic 
protein were used for PCNA and Bcl-2 expression analysis, 
respectively. The samples were separated by electrophoresis 
on 15% denaturing polyacrylamide gel (SDS-PAGE) in 1X 
Tris-glycine buffer. The proteins were then transferred from 
the gel to nitrocellulose membranes and blocked with the 
ECL-advanced kit blocking solution for PCNA analysis or 
with PBS containing 5% powdered milk for Bcl-2 analysis, 
for 1 h. After washing with PBS buffer containing 0.1% 
Tween-20, the membranes were incubated overnight at 4°C 
with the primary anti-PCNA antibody (1:10,000) diluted with 
the ECL-advanced kit blocking solution or with anti-Bcl-2 
antibody (1:500) diluted in milk. The membranes were then 
incubated with the secondary antibody conjugated to horse 
radish peroxidase for 1 h at room temperature. The mem-
branes were developed using the ECL-advanced and ECL 
kit for PCNA and Bcl-2 analysis, respectively. X-ray films 
were then exposed to the membranes. To quantify the band 
intensities, a densitometer (Imaging Densitometer, Model 
GS-700, Bio-Rad, USA) with specific software (Molecular 
Figure 2. Experimental protocol.
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Analyst, Bio-Rad) was used. To control for the amount of 
protein loaded, the nitrocellulose membrane was stained 
with Coomassie blue (8,9,30).
Colonic βI and GO concentrations
βI and GO quantification was performed by the method 
of Su et al. (31) with some modifications. Colonic mucosa 
samples from each group were powdered with liquid N2 and 
homogenized in a Potter homogenizer with 400 µL absolute 
ethanol plus 10 ng methyl-β-ionone and 10 ng thimol (internal 
standard) for the quantification of βI and GO, respectively. 
Homogenates were centrifuged for 15 min at 10,000 g (4°C), 
the supernatants were collected and transferred to clean in-
jection vials and 2 µL was injected into a gas chromatography/
mass spectrometry (GC-MS) system. Standard βI and GO 
solutions plus the same amount of internal standard added 
to the samples were used for the calibration curves that were 
calculated using the analyte/internal standard peak-area 
ratios versus the nominal concentrations of each standard. 
The samples and standards were injected into an HP6890 
gas chromatographer (Agilent, USA) equipped with a CP 
Wax 58 - FFAP (Varian 25 m x 0.32 m x 0.2 µm) column. 
Injection was done in the splitless mode and the injection 
port was maintained at 200°C. The carrier gas used was 
helium, at a flow rate of 1.0 mL/min. The oven temperature 
was maintained at 50°C for 3 min and raised to 250°C at 
20°C/min. The column effluent was monitored by a mass 
selective detector HP5973 (Agilent) using electron impact 
ionization with an ion source at 70 V and 200°C.
Statistical analysis
Data are reported as means ± SEM and all analyses 
were conducted using the STATISTICA 8.0 software (Stat-
soft, USA). Differences were considered to be statistically 
significant when P < 0.05.
Results
Weight gain and diet consumption
No differences were observed between the CO (control), 
βI, GO and βI+GO, groups regarding final body weight and 
average diet consumption during the 9 weeks of the ex-
periment (data not shown). This suggests that isoprenoids 
had no toxicity at the doses administered. It is important to 
emphasize that the doses used (16 mg/100 g body weight 
βI and 25 mg/100 g body weight GO) were much lower than 
the respective LD50 (LD50 of βI = 329 mg/100 g; LD50 of GO 
= 360 mg/100 g) (4,5).
Quantification of ACF in the proximal and distal colon
The βI, GO and βI+GO groups did not differ from the CO 
group in terms of the total number of ACF or ACF <4 or ACF 
≥4 crypts in the proximal colon. 
Figure 3 presents the total number of ACF and the number 
of ACF <4 or ACF ≥4 crypts present in the distal colon of 
animals from the CO, βI, GO, and βI+GO groups. Compared 
to the CO group, the GO group showed a decreased (P ≤ 
0.05) total number of ACF and ACF ≥4 crypts. However, 
there was no difference in the number of ACF <4 crypts in 
the distal colon compared to the CO group. Furthermore, no 
differences were observed between the CO, βI and βI+GO 
groups regarding the total number of ACF, ACF <4 or ACF 
≥4 crypts in the distal colon.
Total plasma cholesterol concentration 
Figure 4 presents the total plasma cholesterol concen-
tration of the N, CO, βI, GO, and βI+GO groups. Compared 
Figure 3. Total number of ACF and number of ACF <4 or ACF ≥4 
crypts present in the distal colon of rats treated with CO, βI, GO, 
or βI+GO during the initiation and post-initiation phases of colon 
carcinogenesis. Doses are given in Figure 2. Data are reported 
as means ± SEM. ACF = aberrant crypt foci; CO = corn oil (N 
= 8); βI = β-ionone (N = 12); GO = geraniol (N = 11); βI+GO = 
combination of βI and GO (N = 11). aP ≤ 0.05 compared to control 
(CO group) (Student t-test for unpaired data).
Figure 4. Total plasma cholesterol concentration of N rats and 
of animals treated with CO, βI, GO, or βI+GO during the initia-
tion and post-initiation phases of colon carcinogenesis. Doses 
are given in Figure 2. Data are reported as means ± SEM. N = 
normal (N = 6); CO = corn oil (N = 8); βI = β-ionone (N = 12); GO 
= geraniol (N = 11); βI+GO = combination of βI and GO (N = 11). 
P ≤ 0.05 when compared to the aN or bCO group (Student t-test 
for unpaired data).
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to the N group, the CO group exhibited an increased (P < 
0.05) plasma cholesterol concentration. Compared with the 
CO group, the βI group exhibited a decreased (P ≤ 0.05) 
plasma cholesterol concentration, while no differences (P 
> 0.05) were observed in the GO and βI+GO groups.
Evaluation of DNA damage in the colonic mucosa
Figure 5 shows the lengths of the comet of the colonic 
mucosa of rats from the N group, treated or not with HP, 
as well as of the colonic mucosa of rats from the CO, βI, 
GO, or βI+GO groups. Normal rat colonic mucosa samples 
treated with HP (HP group) showed comets of increased (P 
≤ 0.05) lengths compared to those observed in the untreated 
ones (N group). When compared to the N group, the CO 
group had comets with increased (P ≤ 0.05) lengths. When 
compared to the CO group, the βI, GO, and βI+GO groups 
had comets with reduced (P ≤ 0.05) lengths, suggesting a 
reduction of DNA damage by isoprenoids. 
Apoptosis in the colonic mucosa
Colonic apoptotic cells were easily detected in HE-
stained sections (Figure 6A). The apoptosis values in the 
proximal and distal colon from the CO, βI, GO, and βI+GO 
groups are shown in Figure 6B and C. Oral treatment 
with βI, GO or βI+GO did not alter the apoptosis levels in 
the proximal colon when compared to the CO group (P > 
0.05). However, a significant increase in apoptosis levels 
was detected in the distal colon from the GO group when 
compared to the CO group (P < 0.05). 
Expression of PCNA and Bcl-2 in the colonic mucosa 
Compared to the N group, the CO group showed a 3.1-
fold increase in PCNA protein expression. No differences 
(P > 0.05) were observed between the CO, βI, GO, and 
βI+GO groups regarding PCNA protein expression. 
Figure 7 shows Bcl-2 expression analysis using cyto-
plasmic protein extracts from the colonic mucosa of rats 
from the N, CO, βI, GO, or βI+GO groups. Compared to 
the N group, the CO group showed a 2.2-fold increase in 
Bcl-2 protein expression. Compared to the CO group, the 
GO group showed a 0.7-fold decrease (P ≤ 0.05) in Bcl-2 
Figure 5. Length of comets of the colonic mucosa of the N group 
that was treated or notb with HP, as well as the colonic mucosa of 
the CO, βI, GO, or βI+GO groups during the initiation and post-
initiation phases of colon carcinogenesis. Doses are given in Fig-
ure 2. Data are reported as means ± SEM. N = normal (N = 6); 
CO = corn oil (N = 8); βI = β-ionone (N = 12); GO = geraniol (N = 
11); βI+GO = combination of βI and GO (N = 11); HP = hydrogen 
peroxide. aPositive Comet assay controls; bNegative Comet as-
say controls. P ≤ 0.05 compared to the cN or dCO group (Student 
t-test for unpaired data).
Figure 6. A, Photomicrographs of colonic apoptotic cell (arrow) identified in an HE-stained section. B, Mean number of 
apoptotic cells per colonic crypt area (mm2) in the proximal colon. C, Mean number of apoptotic cells per colonic crypt area 
(mm2) in the distal colon. Doses are given in Figure 2. Bar = 10 µm. CO = corn oil; βI = β-ionone; GO = geraniol; βI+GO = 
combination of βI and GO. aP ≤ 0.05 compared to control (CO) (Student t-test for unpaired data).
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protein expression while no differences (P > 0.05) were 
observed in the βI and βI+GO groups.
Concentration of βI and GO in the colonic mucosa
βI was not detected in the N, CO or GO groups. Com-
pared to the CO group, the βI and βI+GO groups had higher 
(P ≤ 0.05) colonic mucosa concentrations of βI. Compared 
to the βI group, the βI+GO group had a lower (P ≤ 0.05) 
colonic mucosa concentration of βI. There was no differ-
ence (P > 0.05) in the colonic mucosa concentration of 
GO between the N and CO groups. Compared to the CO 
group, the GO group had a higher (P ≤ 0.05) colonic mucosa 
concentration of GO, while no differences were observed in 
the βI and βI+GO groups. Compared to the GO group, the 
βI+GO group showed a lower (P ≤ 0.05) colonic mucosa 
concentration of GO.
Discussion
The distal portion of the colon is the region where the 
incidence of neoplasms is most frequent in both rats and 
humans (32,33). The new data presented here showing that 
treatment with GO reduced the total number of ACF in this 
region, as well as the number of ACF ≥4 crypts, lesions with 
a more advanced and aggressive phenotype (33), reinforce 
the idea that acyclic isoprenoids may be a chemopreven-
tive agent against colon carcinogenesis. To the best of our 
knowledge, in vivo studies of chemoprevention with GO have 
only been conducted in liver, breast and pancreas carcino-
genesis models, with inhibition of hepatic PNLs (9,10) and 
mammary (11,34) and pancreatic (12) neoplastic lesions, 
respectively. Recently, βI was reported to have chemo-
preventive activity in liver (8,10), breast (3,11) and colon 
(14) carcinogenesis. However, inhibition of total ACF and 
of ACF <4 or ACF ≥4 crypts by βI was not observed in the 
present study. Differences in the experimental design, such 
as the type of carcinogen, dose and mode of administration 
of βI and the strain of animals employed, could explain the 
differences in the results obtained by Janakiram et al. (14) 
and by us. Unexpectedly, the combination of βI and GO 
did not provide chemopreventive effects. 
On the basis of in vitro studies conducted with combi-
nations of isoprenoids, it has been proposed that the less 
potent compound could attenuate the tumor-suppressive 
action of the more potent one (25). We investigated whether 
this absence of chemoprevention was due to alterations 
in the distribution of isoprenoids. We determined the con-
centrations of βI and GO in the colonic mucosa. Treatment 
with each compound individuals increased their respective 
concentration in the colonic mucosa. Animals treated with 
a mixture of the isoprenoids showed that the βI plus GO 
had lower concentrations compared to animals that were 
given βI and GO individually. It is possible that the reduced 
concentration of GO in the colonic mucosa was not sufficient 
to attain protective effects, suggesting that, when consider-
ing the combination of isoprenoids as a chemopreventive 
strategy, bioavailability issues should be considered.
Loss of the regulatory mechanism of HMG-CoA re-
ductase and increase in cholesterol synthesis have been 
reported to occur during carcinogenesis (6). This could 
explain the higher cholesterol concentration in the CO 
group, as compared to the N group. Treatment of birds, 
rats and mice with isoprenoids such as geranylgeraniol, 
limonene or βI resulted in the reduction of HMG-CoA re-
ductase activity that was accompanied by a decrease in 
plasma cholesterol (8,35,36). A decrease in the plasma total 
cholesterol was observed by us in the βI group. Although 
this cyclic isoprenoid did not have chemopreventive activity, 
its hypocholesterolemic effect should be highlighted. The 
chemopreventive activities of GO were not accompanied 
by a decrease in plasma cholesterol concentrations. Simi-
lar results were observed by others after treatment with 
farnesol, lanosterol and squalene of animals with colon 
carcinogenesis, and with GO in pancreas carcinogenesis 
(12,16,18). As previously reported (9,19,37), the chemo-
preventive effect of GO may not involve the inhibition of 
HMG-CoA reductase activity.
Figure 7. A, Bcl-2 Western blot analysis performed with cyto-
plasmic proteins extracted from the colonic mucosa of N rats and 
of animals treated with CO, βI, GO, or βI+GO during the initiation 
and post-initiation phases of colon carcinogenesis. Representa-
tive sample from 1 animal of the N group and from 2 animals from 
all other groups; a total of 3 (N group) and 6 (all other groups) 
animals were analyzed. B, Coomassie blue staining of the mem-
brane as loading control. C, Quantification of membrane Bcl-2 
levels in colon mucosa samples of N rats and animals treated 
with CO, βI, GO, or βI+GO during the initiation and post-initia-
tion phases of colon carcinogenesis. The results are reported 
in relation to N animal colon mucosa, whose Bcl-2 protein level 
was considered as 1. Data are reported as means ± SEM. N = 
normal; CO = corn oil; βI = β-ionone; GO = geraniol; βI+GO = 
combination of βI and GO. aP ≤ 0.05 compared to the CO group 
(Student t-test for unpaired data).
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Dietary isoprenoids such as βI and GO have been shown 
to have antioxidant properties (14,24,38). Treatment with 
these isoprenoids, individually or in combination, reduced 
DNA damage although only GO exhibited anticarcinogenic 
effects. It is important to mention that the Comet assay was 
performed under alkaline conditions that enable the detec-
tion of single- and double-stranded breaks, incomplete repair 
sites and alkali-labile sites, extending the amount of damage 
that can be detected when compared to neutral conditions 
(39). These results suggest that antioxidant effects are not 
involved in the chemopreventive activity of GO during colon 
carcinogenesis. Since the induction of apoptosis could be 
associated with the anticarcinogenic effects of GO (9,10), 
colonic apoptotic cells were quantified in the present study 
using established morphological criteria (27). Although GO 
inhibited DNA damage, the isoprenoid induced apoptosis 
specifically in the distal colon, suggesting that cell death 
induction could represent an important feature of the pro-
tective effects of GO.
Increase in the anti-apoptotic Bcl-2 protein occurs in 
the initial phases of colon carcinogenesis (23), as also 
observed in the present study. Only the GO group exhibited 
lower levels of Bcl-2, suggesting that the inhibition of this 
protein could have a relevant role in apoptosis induction 
by this isoprenoid. The induction of apoptosis via the Bcl-2 
family of proteins has been identified as one of the main 
mechanisms of action of isoprenoids, as observed for 
perillyl alcohol, geranylgeraniol and farnesol (21,22). It is 
important to highlight the lack of in vivo studies addressing 
the capacity of apoptosis modulation by GO, as induced in 
hepatic PNL (9,10). Moreover, since apoptosis is a cellular 
event that involves activation and/or suppression of vari-
ous gene families (23), it would be important to determine 
the influence of GO on other members of the Bcl-2 family, 
including pro-apoptotic ones such as Bax (22).
In the present study, an increase in PCNA protein was 
observed in rats subjected to colon carcinogenesis, which 
could indicate an increase in cell proliferation (40). On the 
other hand, none of the treatments with isoprenoids reduced 
the expression of this protein, suggesting that cell proliferation 
inhibition is not part of the chemopreventive activity of GO. 
The present study advances our knowledge regarding 
the potential of dietary isoprenoids for the chemopreven-
tion of colon carcinogenesis. GO represents a promising 
agent with inhibitory actions on colonic PNLs that are de-
scribed here for the first time. Surprisingly, βI had little or 
no activity. Although the combination of cyclic and acyclic 
isoprenoids has been suggested as a synergistic chemo-
preventive strategy, issues such as bioavailability should 
be considered. 
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